Pulmonx (Pulmonx) Total Inventories : $17.23 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Total Inventories?

Pulmonx's total inventories for the quarter that ended in Mar. 2024 was $17.23 Mil. Pulmonx's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $16.99 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pulmonx's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $2.02.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Pulmonx's Days Inventory for the three months ended in Mar. 2024 was 324.52.

Inventory Turnover measures how fast the company turns over its inventory within a year. Pulmonx's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.28.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Pulmonx's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.90.

Pulmonx Total Inventories Historical Data

The historical data trend for Pulmonx's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Total Inventories Chart

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

5.61

10.74

16.29

14.56

16.74

Pulmonx Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															15.59	15.64	16.13	16.74	17.23

Pulmonx Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Pulmonx (NAS:LUNG) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Pulmonx's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(116.131	+	0.75 * 10.522	+	0.5 * 17.228	-	54.086
-	0	-	0)	/	38.8122
=	2.02

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Pulmonx's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	16.9855	/	4.776	*	365 / 4
	=	324.52

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Pulmonx's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	4.776	/	16.9855
	=	0.28

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Pulmonx's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	16.9855	/	18.854
	=	0.90

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Pulmonx Total Inventories Related Terms

Thank you for viewing the detailed overview of Pulmonx's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx (Pulmonx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

4NI:Germany

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Executives

French Glendon E. Iii	director, officer: President and CEO	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose	officer: Chief Commercial Officer	5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune	officer: Interim CFO	46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp	10 percent owner	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin	director	56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns	director	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou	director	C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51